Pear Therapeutics’s nine-month data is an extra shot in the prescription digital therapeutic’s (PDT) arm as it is in the process of going public with a special purpose acquisition company (SPAC).
The results are from an extended retrospective analysis of real-world data analyzing healthcare resource utilization for reSET-O, a PDT, for the treatment of opioid use disorder (OUD).
Results from a nine-month real-world data analysis show a continued long-term reduction in costly healthcare utilization categories including inpatient (IP) stays and emergency department (ED) visits in patients with OUD.
- ID stays and ED visits decreased by 50% and 27%, respectively in the 9-month post-index period versus the 9-month pre-index period (i.e., pre-reSET-O initiation).
- Quarterly reductions in healthcare utilization were sustained in the 9-month analysis. A total of 18 IP stays and 79 ED visits were recorded during months 6 to 9, versus 32 IP stays and 97 ED visits in months 3 to 6.
- Utilization of drug testing and adjunct counseling sessions decreased in months 6 to 9 (drug tests: 1,905; counseling sessions: 1,309) compared to the 6-month pre-index (drug tests: 2,192; counseling sessions: 1,421) and post-index periods (drug tests: 2,028; counseling sessions: 1,373), suggesting a possible stabilization of patient outcomes 9 months following initiation of reSET-O.
- Buprenorphine adherence increased from 74% to 82% (pre- vs. post-index), suggesting that use of reSET-O is associated with increased medication use.
The analysis, published in the peer-reviewed journal Expert Review of Pharmacoeconomics & Outcomes Research, suggests a possible durability of the reSET-O treatment effect and a long-term stabilization of the clinical trajectory for patients in recovery from OUD, and indicate a strong potential for the cost effectiveness of reSET-O in real-world care settings.
“These findings show how reSET-O can improve total quality of care while reducing the main healthcare cost drivers in OUD,” said Corey McCann, MD, PhD., President and CEO of Pear Therapeutics. “Opioid misuse and overdoses continue to be at epidemic levels in the United States, and patients need access to durable evidence-based behavioral interventions that keep them in recovery, while reducing healthcare costs. In this critical time, patients need more flexible approaches to treatment that can be delivered remotely and that can scale-up during times of increased demand for behavioral health and substance use recovery service.”
Like traditional medicines, PDTs are developed in a GMP-compliant environment, tested in randomized controlled trials demonstrating safety and efficacy, evaluated and authorized by regulators like the FDA, and used under the supervision of a prescribing clinician.
Unlike traditional medicines, PDTs are software applications and are designed to collect real world data for use by prescribing clinicians and by payors and health systems for population health management.
In June, Pear Therapeutics announced it was going public via a SPAC merger with Thimble Point Acquisition Corp. The merger is set to close in the second half of this year and the combined business would have a combined equity value of $1.6 billion with an expected $400 million in gross proceeds.